CVS Health Receives a Buy from SunTrust Robinson

By Ryan Adsit

In a report issued on October 10, David S Macdonald from SunTrust Robinson reiterated a Buy rating on CVS Health (NYSE: CVS), with a price target of $96. The company’s shares opened today at $73.90.

According to, Macdonald is a 1-star analyst with an average return of -0.1% and a 52.5% success rate. Macdonald covers the Services sector, focusing on stocks such as American Renal Associates Holdings Inc, Fresenius Medical Care Corp, and Walgreens Boots Alliance.

Currently, the analyst consensus on CVS Health is Moderate Buy and the average price target is $88.86, representing a 20.2% upside.

In a report issued on October 9, Oppenheimer also assigned a Buy rating to the stock with a $95 price target.

Based on CVS Health’s latest earnings report for the quarter ending June 30, the company posted quarterly revenue of $45.69 billion and quarterly net profit of $1.1 billion. In comparison, last year the company earned revenue of $44.62 billion and had a net profit of $1.53 billion.

Based on the recent corporate insider activity of 76 insiders, corporate insider sentiment is negative on the stock.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

CVS Health Corp. engages in the provision of health care services. It operates trough the following segments: Pharmacy Services, Retail or Long Term Care, and Corporate. The Pharmacy Services segment offers pharmacy benefit management solutions. The Retail or Long Term Care segment includes selling of prescription drugs and assortment of general merchandise.